Vivotif / Bavarian Nordic, Emergent Biosolutions - LARVOL DELTA

Induction of Gut Permeability by an Oral Vaccine (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: USDA, Western Human Nutrition Research Center | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Infectious Disease • Inflammation • LBP

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: USDA, Western Human Nutrition Research Center | Recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Jun 2025 | Trial primary completion date: Sep 2025 ➔ Jun 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Inflammation

CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera (clinicaltrials.gov) - P4 | N=240 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: May 2025 ➔ May 2029 | Trial primary completion date: May 2025 ➔ May 2029

Trial completion date • Trial primary completion date • Cholera • Infectious Disease

Induction of Gut Permeability by an Oral Vaccine (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: USDA, Western Human Nutrition Research Center | Trial completion date: Mar 2025 ➔ Sep 2025

Trial completion date • Infectious Disease • Inflammation • LBP

Blood Donor CVD 5000 (clinicaltrials.gov) - P4 | N=150 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: May 2025 ➔ Jun 2030 | Trial primary completion date: May 2025 ➔ Jun 2030

Trial completion date • Trial primary completion date • Infectious Disease • CD8 • IFNG • TNFA

Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever. (PubMed, Microbe Immun) - "Ty21a®, a killed whole-cell vaccine, and Vivotif®, a live-attenuated vaccine, have been available for decades but have relatively short durations of action and only provide partial protection...When formulated with Advax-CpG™ adjuvant, Typhax demonstrated promising results in a range of animal models including mice, rabbits, and non-human primates in which it induces high and sustained serum anti-Vi immunoglobulin G and serum bactericidal activity, without any safety or reactogenicity issues. This novel vaccine approach offers the potential for a low-cost, more effective, and durable vaccine against typhoid fever, avoiding the need for frequent booster doses."

Journal • Infectious Disease

Induction of Gut Permeability by an Oral Vaccine (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: USDA, Western Human Nutrition Research Center | Trial completion date: Sep 2024 ➔ Mar 2025

Trial completion date • Infectious Disease • Inflammation

CVD 37000: Immunity and Microbiome Studies At Intestinal and Systemic Sites in Ty21a Vaccinated Adults (clinicaltrials.gov) - P4 | N=87 | Active, not recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Jun 2024 ➔ Aug 2027 | Trial primary completion date: Jun 2024 ➔ Aug 2027

Trial completion date • Trial primary completion date • Infectious Disease • CD8 • IFNG • TNFA

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (clinicaltrials.gov) - P4 | N=65 | Completed | Sponsor: Helsinki University Central Hospital | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2024 | Trial primary completion date: Dec 2025 ➔ Jun 2024

Trial completion • Trial completion date • Trial primary completion date • Cholera • Infectious Disease

WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: USDA, Western Human Nutrition Research Center | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Infectious Disease • Inflammation

SLVP033: Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Hepatology • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera (clinicaltrials.gov) - P4 | N=240 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Oct 2023 ➔ May 2025 | Trial primary completion date: Oct 2023 ➔ May 2025

Trial completion date • Trial primary completion date • Cholera • Infectious Disease • CD8 • IFNG • TNFA

Blood Donor CVD 5000 (clinicaltrials.gov) - P4 | N=150 | Recruiting | Sponsor: University of Maryland, Baltimore | Trial completion date: Jun 2024 ➔ May 2025 | Trial primary completion date: Jun 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Infectious Disease • CD8 • IFNG • TNFA

Induction of Gut Permeability by an Oral Vaccine (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: USDA, Western Human Nutrition Research Center | Trial completion date: Sep 2023 ➔ Sep 2024

Trial completion date • Infectious Disease • Inflammation

Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential. (PubMed, J Immunother Cancer) - P1 | "Ty21a immunotherapy of patient with NMIBC is promising with fewer inflammatory cytokines and mild AE, but induction of immune responses with possible antitumor potentials. Future phase II clinical trials are necessary to explore possible efficacy of intravesical Ty21a."

Journal • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Oncology • Solid Tumor

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Helsinki University Central Hospital

New P4 trial • Cholera • Infectious Disease